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Therapeutic upregulation of macroautophagy in can-
cer cells provides an alternative mechanism for cell
death. Prolactin (PRL) and its receptor (PRLR) are
considered attractive therapeutic targets because of
their roles as growth factors in tumor growth and pro-
gression.We utilizedG129R, an antagonist peptide of
PRL, to block activity of the tumoral PRL/PRLR axis,
which resulted in inhibition of tumor growth in ortho-
topic models of human ovarian cancer. Prolonged
treatment with G129R induced the accumulation of
redundant autolysosomes in 3D cancer spheroids,
leading toa type IIprogrammedcell death.This induc-
ible autophagy was a noncanonical beclin-1-inde-
pendent pathway andwas sustained by an astrocytic
phosphoprotein (PEA-15) and protein kinase C zeta
interactome. Lower levels of tumoral PRL/PRLR
in clinical samples were associated with longer
patient survival. Our findings provide an understand-
ing of the mechanisms of tumor growth inhibition
through targeting PRL/PRLR and may have clinical
implications.
INTRODUCTION
The multifunctional hormone, prolactin (PRL), is not only essen-
tial for normal reproduction and maintenance of pregnancy but
also contributes to pathogenesis of gynecologic malignances,488 Cell Reports 7, 488–500, April 24, 2014 ª2014 The Authorsincluding ovarian and endometrial cancers (Levina et al., 2009;
Mor et al., 2005; Tan et al., 2011). Human PRL has proprolifera-
tive effects on ovarian and endometrial cancer cells (Asai-Sato
et al., 2005). Recent studies support a robust role for PRL in
ovarian cancer cell survival and invasion, which implicates it as
a therapeutic target (Tan et al., 2011). PRL binding to its
membrane-associated prolactin receptor (PRLR) is followed
by activation of oncogenic signaling pathways such as JAK2
and STAT3, stimulating proliferation of cancer cells and tumor
growth (Rui et al., 1994; Xie et al., 2002). Despite the importance
of the PRL/PRLR-signaling complex in tumor growth, the under-
lying mechanisms are not well understood, and the ability to
target this pathway is limited by incomplete knowledge of its
activity. G129R, a variant of normal human PRL that differs by
a single amino acid substitution mutation, inhibited PRL-induced
oncogenic signaling responsible for cancer cell proliferation
(Llovera et al., 2000).
Autophagy is a lysosome-dependent cellular degradation
pathway that can be triggered by many stimuli, including meta-
bolic stress, hypoxia, or treatment with chemotherapy agents
or radiation (Rubinsztein et al., 2007). Key proteins regulate
the formation and expansion of vesicular structures such
as autophagosomes, which then fuse with lysosomes to form
autolysosomes. Under normal conditions, basal levels of auto-
phagy in proliferative cells function as a survival mechanism
(Mathew et al., 2007). Prolonged exposure to therapeutic
agents, however, can lead to progression of destructive
autophagy and eventual programmed cell death (Dalby et al.,
2010; White et al., 2010). Targeted molecular therapies
that can induce sustained autophagy offer new therapeutic
opportunities (Shimizu et al., 2004), particularly in breast,
Figure 1. G129R Inhibited Tumor Growth in
Ovarian Cancer Models
(A) Left, PRLR-LF was detected in HeyA8 and
SKOV3 cells treated with PRL (0.1 mg/ml), G129R
(10 mg/ml), a combination (PRL+G129R), or con-
trol (CTL). Right, the fold gel density was normal-
ized to that of b-actin.
(B) Effects of G129R and paclitaxel on tumor
growth in HeyA8 and SKOV3 orthotopic mouse
models. Weight of the tumor from each mouse is
shown; left, HeyA8: *p < 0.05 (CTL versus G129R);
**p < 0.001 (CTL versus G129R+paclitaxel). Right,
SKOV3: *p < 0.05 (CTL versus G129R); **p < 0.001
(CTL versus G129R+paclitaxel).
(C) Left, representative images of cleaved
caspase-3 in HeyA8 tumor tissues (inset shown at
2003 magnification); the scale bar represents
100 mm. Results were confirmed with triplicate
experiments. Right, percentage of tumor with
cleaved caspase-3 staining is shown graphically
(error bar = 95% confidence interval); differences
between groupswere compared by unpaired two-
tailed t test: n = 5, *p < 0.05 (paclitaxel versus
G129R+paclitaxel).prostate, and ovarian cancers that are known for high
rates of loss of tumor-suppressor gene BECN1 (Liang et al.,
1999).
Here, we describe that prolonged treatment with G129R
antagonized the activities of the tumoral PRL/PRLR axis and
inhibited tumor growth through induction of destructive auto-
phagy. Our results indicate that inhibition of the tumoral PRL/
PRLR axis may have implications for anticancer therapy through
promotion of autophagy-related cell death.
RESULTS
In Vivo Antitumor Efficacy of PRLR Antagonist G129R
To gain insights into the effects of blockade of PRL/PRLR
activities on tumor growth, we evaluated the effects of G129RCell Reports 7, 488–5in orthotopic mouse models of human
ovarian cancers that express PRLR.
Expression of the long form of PRLR
(PRLR-LF; 95 kDa) was detected in both
HeyA8 and SKOV3 ovarian cancer cells
(Figure 1A). An in vivo dose-finding
experiment showed that increasing
doses of G129R (100, 200, or 400 mg
daily) were inversely related to tumor
growth without affecting body weight
(Figures S1A and S1B). Therefore, we
chose the dose of 100 mg per day and
used mannitol as the control because it
is the principal excipient in the G129R
formulation (Wang, 2000). After 28 days
of G129R monotherapy, tumor weights
were 50% lower in both HeyA8 and
SKOV3 models than in controls (Fig-
ure 1B). Given that taxane-based chemo-therapy is used frequently for ovarian cancer, we tested a
combination of G129R and paclitaxel, which resulted in >90%
lower tumor weights than in controls (Figure 1B). The number
of tumor nodules was significantly lower in G129R and
G129R + paclitaxel treatment groups than in controls in
both models (Figures S1C and S1D; p < 0.05). We did not
observe any obvious toxic effects of G129R, as shown by
stability of mouse body weights (Figures S1E and S1F) and
of complete blood counts and by histological evaluation of
organs, including liver, kidney, and spleen, from mice
treated with G129R at 100 mg per day for 2 weeks (Figures
S1G and S1H). We also examined the HeyA8 tumors for level
of cleaved caspase-3, which was significantly higher in the
G129R + paclitaxel group than in the paclitaxel-only group
(Figure 1C).00, April 24, 2014 ª2014 The Authors 489
Figure 2. G129R Inhibited Growth of Tumor Cells in 3D, but Not 2D, Conditions
(A) Effects of G129R on viability of 2D cultured SKOV3 cells. ANOVA analysis was performed to compare the viability of cells treated with G129R at various doses
(0.01–1000 mg/ml) and for various time periods (72 and 96 hr; p > 0.05). OD, optical density.
(B) Effects of G129R on cell proliferation (as measured by 5-ethynyl-20-deoxyuridine [EdU] incorporation assay) of 2D SKOV3 cells. n = 6, p = 0.09 (CTL versus
G129R); p = 0.08 (CTL versus PRL+G129R).
(C) G129R significantly increased the annexin V-positive (AnV+) proportion of SKOV3 cells cultured in 3D, but not 2D, conditions. Representative FACS plots are
shown, and corresponding AnV+ percentages in 3D cultured SKOV3 cells were, by treatment: PRL (6.74%), G129R (23.8%), and PRL+G129R (18.3%); n = 6, *p <
0.001 (CTL versus G129R); **p < 0.001 (CTL versus PRL+G129R).
(D) G129R inhibited the growth of 3D HeyA8 spheroids. Top, representative photomicrographs indicate the approximate time elapsed: (a) 240, (b) 600, and (c)
2800min (seeMovies S1–S4). Bottom, 3D structure scoring was based on the number of 3D cells per high-power field (HPF) after 48 hr of treatment. Over 20HPFs
were scored, and average numbers of cells were graphed. n = 20, **p < 0.01 (PRL versus G129R); *p < 0.05 (PRL versus PRL+G129R).
(E) G129R antagonized PRL activation of JAK2, STAT3, and STAT5 in HeyA8 3D spheroids. The effects of PRL at various doses on phosphorylation of JAK2 and
STAT3/STAT5 were detected after 1 hr of treatment. The antagonistic effect of G129R against PRL was captured by adding a combination of PRL (0.5 mg/ml) and
G129R (10 mg/ml).Inhibition of Tumor Cell Growth by G129R in 3D, but Not
2D, Conditions
To identify themechanismof G129R’s inhibition of tumor growth,
we examined the effects of G129R in vitro in ovarian cancer cell
lines. We observed no significant effects on cell viability or
proliferative property of SKOV3 cells under 2D conditions (Fig-
ures 2A and 2B; p > 0.05). Moreover, G129R had no significant
effect on migration or invasive properties of HeyA8, SKOV3, or
IG10 cells cultured under 2D monolayer conditions (Figures
S2A, 2B, and 2C).490 Cell Reports 7, 488–500, April 24, 2014 ª2014 The AuthorsGiven the substantial difference between the effects of
G129R in in vivo and 2D conditions, we reasoned that the
inhibitory mechanism of G129R may be recapitulated by 3D
cultured cancer spheroids (Debnath and Brugge, 2005).
G129R did not significantly increase the percentage of annexin
V-positive SKOV3 cells in 2D culture but significantly increased
the percentage of annexin V-positive 3D SKOV3 spheroids
(Figure 2C). Similar results were noted with the 3D cultured
HeyA8 cells (Figure S2D), but not IG10 cells, which have very
low levels of endogenous PRLR-LF, suggesting that the 3D
growth inhibition induced by G129R depends on PRLR-LF
expression.
We next utilized time-lapse video microscopy to monitor the
longitudinal effects of G129R in 3D cancer spheroids. The
growth of 3D spheroids was significantly faster in the control or
PRL-treated groups (Figure 2D; Movies S1 and S2) than in
the groups treated with G129R or PRL+G129R (Figure 2D;
Movies S3 and S4). The number of 3D cultured cells in spheroids
per high-power field for each group was statistically analyzed
at the end of each video. The numbers of G129R-treated or
PRL+G129R-treated spheroids were significantly lower than
the numbers of PRL-treated spheroids (Figure 2D). Moreover,
PRL+G129R treatment blocked activation of JAK2, STAT3,
and STAT5 in 3D cultured HeyA8 cells (Figure 2E), which showed
that the inhibition of oncogenic JAK2-STATs pathways by
G129R is mediated through antagonism of the PRL/PRLR axis.
Sustained Autophagy following G129R Treatment
To gain insight into mechanisms of growth inhibition by G129R,
we analyzed the proteomic profile of HeyA8 3D spheroids using
reverse-phase protein array analysis (RPPA) and found that a
number of autophagic factors were upregulated by treatment
with G129R or PRL+G129R, including beclin-1 and phosphopro-
tein enriched in astrocytes (PEA-15; Figure 3A). We also
analyzed the genomic profile of HeyA8 3D spheroids regulated
by G129R. Multiple genes involved in autophagy progression
and cell death, including ATG14, ATG16L1, ATG7, BCL2 (Akar
et al., 2008; Levine et al., 2008), BIRC2 (Meng et al., 2010),
BNIP3 (Quinsay et al., 2010), CAPN1 (Demarchi et al., 2007),
CASP1, CASP2, MAP1_LC3_1A, MMP10, PEA-15 (Bartholo-
meusz et al., 2008), PINK1, and others, were upregulated by
G129R treatment. Among the upregulated genes, ATG7 is
known to be involved in triggering autophagic cell death (Yu
et al., 2004); others have known activity in autophagy (marked
by asterisks in Figure 3B).
We next used acridine orange (AO) to stain the acidic vesicular
organelles (AVOs) in G129R-treated cancer cell spheroids
and analyzed them by fluorescence-activated cell sorting
(FACS). There were significantly more AO-positive cells (i.e.,
AVOs) in HeyA8 3D spheroids treated with G129R (18.8%) or
PRL+G129R (18.4%) than in controls (6.2%) or PRL-treated 3D
spheroids (1.62%; Figure 3C). Similar results were not observed
in 2D cultured HeyA8 cells (Figure S2E). In addition, we observed
no significant effects of G129R on IG10 cells with low-level
PRLR-LF (Figure S2E).
Next, we employed transmission election microscopy to
identify the subcellular organelles formed in PRL-treated (Fig-
ure 3D) and G129R-treated (Figure 3E) 3D spheroids. G129R
treatment induced substantial amounts of autophagosomes and
late autophagic vacuoles, or autolysosomes. Furthermore, the
G129R-treated HeyA8 spheroids had intact nuclear membranes
and no apoptosomes. We did not observe the same amounts of
autophagosomes or autolysosomes in PRL-treated 3D spheroids
(Figure 3D; high-resolution images are shown in Figure S2F).
We then performed monomeric pGFP-red fluorescent protein
(RFP)-light chain 3 (LC3) microscopy to monitor autophagic
flux in 3D cancer cell spheroids (Klionsky et al., 2012). A
pEGFP-RFP-tagged microtubule-associated protein 1 LC3plasmid (Kimura et al., 2007) was stably transfected into
HeyA8 cells prior to 3D culture. The monomeric GFP (mGFP)
protein is acid sensitive and is degraded following fusion of
autophagosomes with lysosomes, whereas the mRFP is
relatively stable. PRL-treated HeyA8 3D cancer spheroids
expressed little GFP or RFP signal, which indicated that PRL
did not induce formation of autophagosomes (Figure 3F).
However, we observed autophagic puncta with mGFP/mRFP-
merged signals in cytoplasm of G129R-treated HeyA8 3D
spheroids, which indicated the formation of autophagosomes
(RFP+andGFP+LC3; Figure 3G). More importantly, as a result of
autophagic flux and quenching of acid-sensitive fluorescent
signal of GFP due to low pH in the lysosomes, presence of red
puncta by RFP+onlyLC3 (RFP+GFP) became highly visible under
the treatment of G129R, representing the formation of autoly-
sosomes (Figure 3G). The autophagic vesicles expressing
RFP+andGFP+LC3 were validated in HeyA8 3D cancer spheroids
treated with rapamycin (50 nM) for 24 hr (Figure 3H).
To quantitatively measure the autophagic flux in a high-
throughput manner, we used FACS to count the late-stage auto-
lysosomes (RFP+). Treatment with G129R induced a significant
shift toward RFP+LC3 in comparison with control or PRL treat-
ment (Figure 3I). These findings indicate that, different from
rapamycin, G129R induces substantial autophagy in 3D cancer
spheroids by forming abundant autophagic vacuoles, particu-
larly autolysosomes. To distinguish the autophagy induced by
G129R, we further compared the GFP+LC3 and RFP+LC3 popu-
lations of 3D HeyA8 cells following treatment with rapamycin
or G129R. In comparison with control, rapamycin (50 nM)
increased both GFP+ and RFP+ populations, whereas G129R
increased the population of RFP+LC3, but not GFP+ (Figures
3J and 3K). Using time-lapse video microscopy, we monitored
the conversion of 3D cancer spheroids from GFP+andRFP+LC3
to RFP+onlyLC3 following prolonged treatment with G129R;
the 3D spheroids treated with rapamycin remained GFP+and
RFP+LC3 (Figure S3A; Movies S5 and S6). Thus, our results
indicate that rapamycin induced autophagosomes containing
GFP+andRFP+ LC3, whereas G129R induced enrichment of
late-stage autolysosomes containing RFP+onlyLC3.
To determine the effects of G129R-induced autophagy in cell
survival, we measured the viability of 3D cultured cancer spher-
oids. Under 2D conditions, neither G129R nor PRL+G129R
changed the viability of HeyA8 or SKOV3 cells. However,
G129R significantly decreased the viability of cells cultured un-
der 3D conditions (Figure S3B). The inhibitory effect of G129R
under 3D conditions was reversed by addition of autophagy
inhibitors bafilomycin A1 (Yamamoto et al., 1998) or hydroxy-
chloroquine (Amaravadi et al., 2011). The cell death was further
validated by FACS analysis with SYTOX green (Figure S3C).
We confirmed this finding by examining the conversion of LC3
from isoform I to II (Klionsky et al., 2012) under these conditions
and found the same results: the autophagy inhibitors reversed
effects of G129R on LC3-I/II conversion (Figure S3D).
G129R-Induced Autophagy Is Mediated by PEA-15
To explore the mechanism of autophagy induced by G129R, we
examined an array of autophagic factors identified in Figure 3.
We used a short hairpin RNA (shRNA) complex against BECN1Cell Reports 7, 488–500, April 24, 2014 ª2014 The Authors 491
Figure 3. Autophagy in 3D Cancer Spheroids
Was Induced by G129R
(A) Top, heatmap clustered from RPPA analysis
revealed an array of autophagic factors in HeyA8 3D
spheroids regulated by G129R or PRL+G129R. B
Graph of normalized fold changes indicated that
PEA-15 was increased by G129R or PRL+G129R as
compared to PRL.
(B) Heatmap clustered from cDNAmicroarray analysis
identified genes involved in autophagy that were up-
regulated by G129R in HeyA8 3D spheroids (one-way
ANOVA; n = 3; p < 0.001). Genes denoted with as-
terisks are those with roles in autophagy.
(C) Representative FACS plot showed the percentage
of acidic vesicular organelles (AVOs, as detected by
AO staining) in HeyA8 3D spheroids treated with PRL
or PRL+G129R; corresponding AVO percentages
were, by treatment: PRL (1.62%), G129R (18.8%),
PRL+G129R (18.4%). n = 6, *p < 0.05 (CTL versus
G129R); **p < 0.001 (CTL versus PRL+G129R).
(D and E) Representative images from transmission
electron microscopy showed autophagic vesicles
formed in HeyA8 3D spheroids treated with PRL (D) or
G129R (E). Substantial amounts of autophagosomes
(green arrows) and autolysosomes (blue arrows) were
identified in the cytoplasm of the G129R-treated
spheroids, whereas no such structure was observed
in PRL-treated spheroids. Substructure was observed
under 5,0003 and 20,0003 magnification. Ultrathin
sections in representative areas from 15 fields are
shown. For higher resolution images, please refer to
Figure S2E.
(F–H) Tandem LC3 microscopy showed autophagic
flux in pGFP-RFP-LC3-expressing HeyA8 3D spher-
oids treated with PRL (F) or G129R (G) for 72 hr or
50 nM rapamycin (H) for 24 hr. Vesicles containing
both GFP+ and RFP+LC3 represent early-stage
autophagosomes (green arrow), whereas vesicles
containing RFP+LC3 only represent late-stage auto-
lysosomes (blue arrow). The scale bars in (F) and (H)
represent 10 mm; the scale bar in (G) represents 20 mm.
(I) FACS analysis indicated a significant shift of the
RFP+ population for HeyA8 3D spheroids treated with
G129R in comparison with PRL or CTL.
(J and K) FACS analysis for GFP+LC3 or RFP+LC3
population of HeyA8 spheroids treated with rapamy-
cin (50 nM; J) or G129R (10 mg/ml; K) indicated the
differential effects of rapamycin and G129R in auto-
phagy.
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to knock down beclin-1 in HeyA8 cells and discovered that
knockdown of beclin-1 did not decrease the autophagic flux in
HeyA8 3D spheroids treated with G129R, as shown by FACS
analysis of AO staining and LC3-I/II conversion (Figures S4A
and S4B). The proportions of autolysosomes containing
RFP+LC3 in 3D HeyA8 spheroids treated with G129R alone
were not significantly different than those in HeyA8-shBECN1
spheroids treated with G129R (Figures S4C and S4D). However,
when we targeted ATG7 with shRNA in HeyA8 spheroids, the
G129R-induced LC3-I/II conversion and enrichment of
RFP+LC3-containing autolysosomes were reversed by ATG7
knockdown (Figures S4E and S4F). Additionally, G129R signifi-
cantly decreased the viability of HeyA8-shBECN1 spheroids,
but not HeyA8-shATG7 spheroids (Figure S4G). FACS analysis
with SYTOX-green staining showed that shATG7 sufficiently
reversed the cell death induced by G129R; however, shBECN1
did not have such effects (Figure S4H). In addition, we deter-
mined the effect of ATG5 knockdown on cell viability and cell
death in 3D cancer spheroids treated with G129R but did not
observe significant effects from either analysis (data not shown).
These results indicate that G129R-induced autophagy is beclin-
1-independent but executed by ATG7.
Next, we investigated the role of PEA-15 during G129R-
induced autophagy through small interfering RNA (siRNA)
knockdown or adenoviral expression. During the initial 12 hr of
treatment with PRL or G129R, PEA-15 was expressed in
HeyA8 and IG10 cells (Figure 4A), but not in A2780 cells, which
express PRLR-LF (Figure 4B). We manipulated the levels of
PEA-15 in pGFP-RFP-LC3-HeyA8 cells with siRNA (siPEA-15)
or with an adenoviral construct (Ad.PEA-15) and treated these
cells with PRL or G129R. The formation of autophagic vesicles
in these cells was assessed by FACSanalysis of RFP+ (Figure 4C,
left) or by confocal microscopy (Figure 4C, right). Knockdown of
PEA-15 did not induce accumulation of autophagic vacuoles.
Overexpression of PEA-15 enriched autophagosomes contain-
ing EGFP+/RFP+LC3 (Figure 4C and high-resolution images in
Figure S4I), as previously reported (Bartholomeusz et al.,
2008). Interestingly, G129R alone or in combination with Ad.-
PEA-15 significantly increased autolysosomes containing
RFP+LC3 only (Figure 4C, also shown in Figure S4I). This finding
indicates that Ad.PEA-15 was able to initiate autophagy,
whereas G129R substantially enriched the late-stage autolyso-
somes (formed through fusion of autophagosomes and
lysosomes containing RFP+LC3 only). Statistical analysis of
RFP-integrated densities from 15 independent images demon-
strated significantly greater density in cells treated with
G129R+Ad.PEA-15 than in cells treated with Ad.PEA-15
(Figure S4J). Given that G129R significantly decreased the
viability of cancer cell spheroids (Figure S3), these findings of
abundant autolysosomes enriched byG129R point to an alterna-
tive death pathway through sustained autophagy.
We further measured the percentage of AVOs in HeyA8 3D
spheroids. Overexpression of PEA-15 significantly increased
the percentage of AVOs, whereas knockdown of PEA-15
lowered the percentage of AVOs (Figure 4D). Exogenous
PEA-15 increased the percentage of AVOs independent of
G129R. We did not observe the increased AVOs after G129R
treatment in either A2780 or IG10 cells (data not shown), whichlargely lack endogenous PEA-15 or PRLR (A2780, Figure 4A;
IG10, Figure 5H).
We then validated this finding by measuring the LC3-I/II con-
version in HeyA8 3D spheroids. Levels of LC3-II increased within
48 hr of treatment with G129R or Ad.PEA-15 in comparison with
controls (Figure 4E). Fold densities of LC3-II immunoblotting
bands were normalized with b-actin and showed substantial
increases in cells treated with G129R, PRL+G129R, Ad.PEA-15
alone, or Ad.PEA-15+G129R (Figure 4E). Neither A2780 nor
IG10 cells showed such an increase in LC3-II accumulation
(data not shown), indicating that expression of both PEA-15
and PRLR is necessary for G129R-induced autophagy.
Next, we investigated the regulatory machinery between
PEA-15 and PRLR antagonism. Protein kinase C zeta (PKC-z),
a downstream factor of PRLR-LF activation (Crowe et al.,
1991), phosphorylates PEA-15 at serine 104 (S104), enhancing
its stability (Kubes et al., 1998). Levels of PEA-15 and PKC-z in
HeyA8 3D spheroids increased along with duration of G129R
treatment and decreased along with PRL treatment. Both total
and activated forms of PEA-15 and PKC-z reached the highest
levels at 72 hr of G129R treatment (Figure 4F). The accumulation
of LC3-II also reached the highest level at 72 hr following G129R
treatment. Expression of SQSTM1/p62, an adaptor protein
involved in the autophagy process (Dikic et al., 2010), varied
slightly with duration of treatment, possibly because of the ubiq-
uitin-protein degradation processes linked with autophagy pro-
gression. These results indicate that G129R-induced autophagy
is mediated by activation of the PEA-15/PKC-z interactome.
PRLR Depletion Induces Autophagy
To determine whether blockade of PRLR through genetic
ablation induces autophagy, we used shRNA-PRLR and a
heterogeneous mixture of siRNAs (esiRNA) against growth
hormone receptor (GHR) to achieve substantial knockdown of
PRLR and GHR in HeyA8 (Figure 5A) and SKOV3 cells (Fig-
ure 5B). The inclusion of GHR was based on the knowledge
that G129R blocks partial activities of GHR by interfering with
the PRLR/GHR heterodimer (Xu et al., 2011). The conversion of
LC3-I to LC3-II was enhanced in 3D HeyA8 and SKOV3 spher-
oids under PRLR or GHR knockdown. The percentages of
AVOs were significantly increased when PRLR or GHR was
completely depleted (HeyA8, Figure 5C; SKOV3, Figure 5D).
Similar results were observed in the shRNA-PRLR cells treated
with G129R (HeyA8, Figure 5E; SKOV3, Figure 5F), which indi-
cates that G129R did not alter the PRLR depletion-induced auto-
phagy. We then analyzed the autophagic flux by FACS through
quantitation of the subpopulation of RFP+LC3 cells among
pGFP-RFP-LC3-HeyA8 spheroids. Both shRNA-PRLR and esi-
GHR induced a shift of RFP+ expression in comparison with con-
trols (Figure 5G).
In the meantime, we transfected a prlr-open reading frame
(ORF) construct driven by a GFP-tagged pCMV promoter to
increase the expression of PRLR in IG10 cells to levels equivalent
to those in HeyA8 and SKOV3 cells (Figure 5H). The overexpres-
sion of GFP-PRLR in IG10 3D spheroids was shown by confocal
microscopy and immunoblots (Figure 5H). Treatment of PRLR-
positive IG10 spheroids with G129R resulted in significant
increases in percentage of AVOs (G129R+prlr-ORF versusCell Reports 7, 488–500, April 24, 2014 ª2014 The Authors 493
Figure 4. G129R-Induced Autophagy Is Mediated by PEA-15
(A) Expression of PEA-15 in HeyA8, A2780, and IG10 cells.
(B) Expression of PRLR-LF in A2780 cells. Only HeyA8 cells expressed both PRLR-LF and PEA-15.
(legend continued on next page)
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controls, p < 0.05; PRL+G129R+prlr-ORF versus controls, p <
0.05; Figure 5I). No significant changes in percentage of AVOs
were observed in parental IG10 cells treated with G129R in either
2D or 3D conditions (Figure S2E), implying that sufficient PRLR is
necessary for G129R to induce the autophagic vacuoles.
Next, we used PRLR-deficient, GHR-positive LNcap cells (Xu
et al., 2011) to analyze the specificity of G129R in antagonizing
PRLR activity. G129R alone did not induce an increase in the
percentage of AVOs in these cells (Figure S5A), whereas GHR
antagonist B2036, alone or in combination with PRL, increased
the AVOs. This is further supported by the response to G129R
treatment of LNcap cells sensitized by exogenous expression
of prlr-ORF; knockdown of endogenous PEA-15 reduced AVOs
induced by G129R and prlr-ORF (unpaired two-tailed p < 0.05;
Figure S5B). We further determined the in vivo effect of G129R
in LNcap cells using a mouse xenograft model. After 28 days
of treatment, the G129R group had no significant tumor reduc-
tion or loss of body weight compared to the control group (p >
0.05; Figures S5C and S5D). The expression of PRLR-LF was
validated in HeyA8, SKOV3, LNcap, and human embryonic kid-
ney 293T cells (Figure S5E). These data indicate that blockade
of PRLR activity by G129R or by genetic depletion of prlr leads
to inducible autophagy.
To determine if this mechanism of autophagy by G129R is
cancer-type specific, we measured the percentage of AVOs in
two human pancreatic cancer cell lines cultured under 3D
settings: Panc-1 (expressing PEA-15 and PRLR-LF) and
HPAF2 (expressing PEA-15, but not PRLR-LF; Figure S6). The
percentage of AVOs increased significantly upon treatment
with G129R in Panc-1 cells, but not in HPAF2 cells, which indi-
cated that expression of PRLR-LF is also necessary for
G129R-induced autophagy in pancreatic cancer.
High Tumoral PRLR and Low Autophagic Factor
Correlates with Worse Clinical Outcome
We next analyzed the clinical relevance of the PRL/PRLR
axis and autophagic factors. First, we measured levels of
PRL, PRLR, and PEA-15 in serum samples from eight patients
with epithelial ovarian cancer by ELISA; results indicated an
inverse correlation between PRL/PRLR and PEA-15 (PRL/
PRLR, R = 0.92 with high precision; PRLR/PEA-15, R =
0.33 with moderate precision; PRL/PEA-15, R = 0.32 with
moderate precision; Figures 6A and 6B). We then collected
serum and tumor samples from another eight women with
epithelial ovarian cancer. We measured levels of circulating
PRL in serum samples by ELISA and levels of PRL/PRLR(C) Role of PEA-15 in G129R-induced autophagy assessed by tandem tagged LC
were treated with control (CTL)+siPEA-15, PRL+Ad.PEA-15, Ad.PEA-15, Ad.P
analysis indicating percentage of RFP+LC3 cells under each treatment in compar
individual replicates per condition were performed. Right, representative images o
of GFP+andRFP+LC3 in Ad.PEA-15 and RFP+LC3 only in G129R+Ad.PEA-15, ple
(D) Percentage of AVOs in 3D spheroids measured under manipulation of PEA-15
*p < 0.01 (CTL versus CTL+Ad.PEA-15); **p < 0.001 (G129R versus G129R+siPE
(E) Measurement of autophagic flux by LC3-I to -II conversion. Top, expression
Ad.PEA-15. Bottom, gel density of LC3-II in each condition was normalized with
(F) Time dynamics of PEA-15 activation in HeyA8 3D spheroids. Phosphorylat
Phosphorylation of PEA-15 and PKC-z was decreased in spheroids treated with
treatment.protein in tumor homogenates with immunoblotting. Results
showed that PRL/PRLR was inversely correlated with LC3-II,
SQSTM1/p62, and S104-phosphorylated and total PEA-15
(Figure 6C). Immunohistochemical staining confirmed this
finding and also showed an inverse correlation between
PRLR and cleaved caspase-3 (Figure 6D).
We further analyzed tumor samples from a larger cohort of
patients (n = 32) with epithelial ovarian cancer (Table S1). Immu-
nohistochemical analysis showed that, in comparison with
normal ovary, which expressed low levels of GHR and PRLR,
epithelial ovarian tumors expressed higher levels of GHR and
PRLR and lower levels of S104-phosphorylated PEA-15,
SQSTM1/p62, and activated caspase-3 (Figure 7A). Patients
whose tumors expressed relatively lower PRLR and higher
S104-phosphorylated PEA-15 and SQSTM1/p62 had a better
overall survival rate (Figure 7B). These data point to the potential
clinical importance of targeting PRL/PRLR during development
of epithelial ovarian cancer. To extend our finding, we compared
the levels of S104-phosphorylated PEA-15, LC3-II, and cleaved
caspase-3 in ovarian tissues from 4-week-old BL6 wild-type and
prl/ mice (Cruz-Soto et al., 2002) to determine their contribu-
tion during ovarian development. Levels of all three factors
were higher in ovarian tissues from prl/ mice than in those
from the wild-type mice (Figure S7).
In summary, our studies reveal a mechanism for programmed
cell death induced by blockade of tumoral PRL/PRLR in cancer
cells. This cell death occurs through sustained autophagy and
leads to inhibition of tumor growth (depicted schematically in
Figure 7C).
DISCUSSION
Here, we report a previously unrecognized mechanism by which
blockade of the tumoral PRL/PRLR axis induced sustained
autophagy that led to programmed cell death. We demonstrated
an inverse correlation between tumoral PRL/PRLR levels and
autophagic factors in patients with epithelial ovarian cancer
and showed evidence of clinical potential that provides a ratio-
nale for targeting tumoral PRL/PRLR.
Recent studies have shown that levels of PRL were substan-
tially elevated in ovarian cancer patients and concomitantly
enhanced proliferation, migration, and invasion and promoted
tumor angiogenesis (Asai-Sato et al., 2005; Levina et al., 2009).
Our results indicate that antagonism of PRL/PRLR axis enriched
late-stage autophagic vacuoles in cancer cells cultured in 3D
conditions, which led to programmed cell death. This might3microscopy and FACS. The pGFP-RFP-LC3-expressing HeyA8 3D spheroids
EA-15+G129R, or G129R+siPEA-15. Left, histograms show results of FACS
ison with nontreated controls. Each analysis represents 10,000 cells, and three
f cells with GFP+ and RFP+LC3 are shown; n = 20. For higher-resolution images
ase see Figure S4I.
. Knockdown of PEA-15 with siRNA abolished the G129R-induced AVOs. n = 3,
A-15).
of LC3-II was increased in HeyA8 3D spheroids by G129R, PRL+G129R, or
b-actin and measured by ImageJ 3.0.
ion of PEA-15 and PKC-z was detected by pS104 and pT560, respectively.
PRL but increased in those treated with G129R, reaching its peak at 72 hr of
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Figure 5. PRLR Silencing Induced Autophagic Flux in 3D Cancer Spheroids
(A and B) LC3-I to -II conversion in HeyA8 (A) and SKOV3 (B) 3D spheroids stably transfected with shRNA-prlr or esiRNA-GHR, respectively.
(C and D) Knockdown of PRLR or GHR prominently increased percentages of AVOs in HeyA8 (C) and SKOV3 (D) 3D spheroids. n = 3, *p < 0.01 (CTL versus
shRNA-prlr, HeyA8; C); *p < 0.005 (CTL versus shRNA-prlr, SKOV3; D).
(E and F) Increased AVOs in 3D HeyA8 (E) and SKOV3 (F) spheroids induced by PRLR knockdown was not enhanced by G129R. n = 3, *p < 0.01 (CTL versus
G129R+shRNA-prlr; E); *p < 0.05 (CTL versus G129R+shRNA-prlr; F).
(G) FACS analysis for RFP-LC3+ cells showed the shift of the RFP+ population for HeyA8 3D cells transfected with shRNA-PRLR (orange) or esiRNA-GHR (blue)
from that of controls (red).
(H) PRLR was introduced into IG10 spheroids by transfection of a GFP-tagged pCMV-prlr-ORF. Top, representative images indicate the expression of GFP-prlr-
ORF in IG10-3D spheroids; the scale bar represents 5 mm. Bottom, immunoblotting with anti-PRLR (clone BP774) validated PRLR expression.
(I) In prlr-transfected IG10 spheroids, G129R increased the percentages of AVOs. Differences between groups were compared by unpaired two-tailed Student’s
t test: n = 6, *p < 0.05 (CTL versus G129R+prlr-ORF); **p < 0.05 (CTL versus PRL/G129R+prlr-ORF).explain the robust inhibitory effects of G129R on tumor growth
that we observed in vivo, but not in 2D cultured cancer cells.
Persistent metabolic stress, such as that caused by chemo-
therapeutic agents, can induce excessive and sustained auto-
phagy by which tumor cells are eliminated (Bursch et al., 1996;496 Cell Reports 7, 488–500, April 24, 2014 ª2014 The AuthorsCastino et al., 2010; Mathew et al., 2007). Our studies showed
that blockade of PRL/PRLR caused accumulation of substantial
RFP+onlyLC3-containing autolysosomes in 3D cancer spheroids.
The abundant late-stage autophagic vacuoles were death-
switch signals that led to programmed death of cancer cells.
Figure 6. Expression of PRL/PRLR Axis and PEA-15Was Inversely Correlated in Tumor Samples fromWomenwith Epithelial Ovarian Cancer
(A) Levels of PRL (left), PRLR (middle), and PEA-15 (right) were measured by ELISA in tumor samples from eight patients with epithelial ovarian cancer. The y axis
represents the concentration of the proteins (ng/ml) in serum (A) or in tumor homogenates (B and C). Six individual replicates were performed for every ELISA in
each patient.
(B) Pearson correlation of PRL, PRLR, and PEA-15 concentrations in epithelial ovarian cancer patients. Correlation coefficient for PRL versus PRLR, R = 0.921, p <
0.001 (left); correlation coefficient for PRLR versus PEA-15, R = 0.036, p < 0.001 (middle); correlation coefficient for PRL versus PEA-15, R = 0.325, p < 0.05
(right).
(C) Top, levels of PRL (ng/ml) were validated from serum samples of another eight patients with epithelial ovarian cancer. Bottom, expression of PRL, PRLR, LC3,
SQSTM1/p62, and PEA-15 (S104-phosphorylated and total) were further measured by immunoblotting from the tumors homogenates of these patients.
(D) Representative images of immunohistochemical staining of tumor tissues of the eight patients shown in (C) show the inverse PRL-caspase-3, PRL-SQSTM1/
p62 correlations. Hematoxylin and eosin (H&E)-stained images are included to show the presence of tumor. Representative images of each staining were
selected from 15 high-power fields, magnification 2003.We further showed that autophagy induced by blockade of
PRL/PRLR is mediated by the PEA-15/PKC-z interactome. This
finding is consistent with recent reports regarding the role of
PEA-15 in activating cell death in breast cancer cells (Bartholo-
meusz et al., 2010). We discovered that the function of PEA-15in mediating G129R-induced autophagy requires stabilization
of the protein. Kinase PKC-z reportedly enhances PEA-15 stabil-
ity (Trencia et al., 2003). We showed that levels of PKC-z and
S104-phosphorylated PEA-15 increased following G129R treat-
ment, suggesting that S104-phosphorylated PEA-15 is tumorCell Reports 7, 488–500, April 24, 2014 ª2014 The Authors 497
Figure 7. High Levels of PRLR and Low Levels of Autophagic Factors Correlated with Worse Prognosis
(A) Representative images of immunohistochemical analysis for GHR, PRLR, S104-phosphorylated PEA-15, SQSTM1/p62, and cleaved caspase-3 on tissue
sections from a larger cohort of patients with epithelial ovarian cancer (n = 32) are shown. Magnification 1003. Top, isotype control in the normal ovary (left);
isotype control in the tumor (right). Bottom, expression of GHR, PRLR, S104-phosphorylated PEA-15, SQSTM1/p62, and cleaved caspase-3 in normal ovaries
and ovarian cancers are shown in representative images. Patients 1 and 2 represent advanced stages of disease (FIGO IIIb and FIGO IIIc, respectively), and
patients 3 and 4 represent early stages of disease (FIGO Ia and FIGO Ib, respectively).
(B) Patients with a low level of PRLR and high levels of PEA-15 and SQSTM1/p62 had a better survival rate. Analysis of PRLR staining patterns and overall survival:
(POSITIVITY) 1 = positive, 2 = heterogeneous, 3 = negative; (INTENSITY) 1 = strong, 2 = moderate, 3 = weak, 4 = none. Analysis of PEA-15 staining pattern and
overall survival: (POSITIVITY) 1 = negative, 2 = positive; (INTENSITY) 1 = none, 2 = weak, 3 = moderate, 4 = strong. Analysis of SQSTM1/p62 staining pattern and
overall survival: (POSITIVITY) 1 = negative, 2 = heterogeneous, 3 = positive; (INTENSITY) 1 = none, 2 = weak, 3 = moderate, 4 = strong.
(C) Schematic illustration of divergent mechanisms induced by blockade of PRL/PRLR in tumor cells.suppressive by contributing to G129R-induced growth inhibi-
tion. This finding diverges from a recent report that S104 phos-
phorylation is a switch to turn PEA-15 from tumor suppressor498 Cell Reports 7, 488–500, April 24, 2014 ª2014 The Authorsto tumor promoter (Sulzmaier et al., 2012). Further studies are
needed to define the role of S104-PEA-15 in the tumor-inhibitory
effect of blockade of PRL/PRLR.
Until now, there has been no report on the clinical correlation
of autophagic factors with ovarian cancer progression. Our
studies revealed an inverse correlation between expression of
tumoral PRL/PRLR and of autophagy markers (e.g., LC3-II) and
regulatory factors (e.g., SQSTM1/p62 and S104-PEA-15) in
tumor samples from women with epithelial ovarian cancer. We
demonstrated the prognostic significance of these markers:
higher levels of tumoral PRL/PRLR axis and lower levels of
PEA-15, SQSTM1/p62, and cleaved caspase-3 were associated
with lower survival rate. This finding provides clinical rationale for
targeting the tumoral PRL/PRLR axis and promoting cell death
through autophagy as an alternative strategy for treating malig-
nant tumors, particularly those with apoptotic resistance.
EXPERIMENTAL PROCEDURES
Reagents and Plasmids
G129R was supplied by Oncolix. The PEA-15 siRNA (ggaagacauccccagc
gaatt) was described previously (Bartholomeusz et al., 2010). Adenoviral
PEA-15 (Ad.PEA-15) was constructed by inserting PEA-15 cDNA into the
adenoviral vector pAdTrack-cytomegalovirus immediate early promoter
(CMV) (He et al., 1998). The esiRNA against GHR was purchased from
Sigma-Aldrich. The shRNA against BECN-1 or ATG7 and siRNA against
ATG5 were purchased from OriGene. The siRNAs were applied to cells at a
final concentration of 100 nmol/l for 48 hr. Transfections of the pEGFP-tagged
pCMV-prlr-ORF clone of PRLR, shRNA-PRLR, shATG7, or shRNA-BECN1 4
29-mer mix (human) were performed according to the manufacturer’s instruc-
tions. The pEGFP-RFP-LC3 plasmid was derived from Addgene plasmid
21074. Anti-PRLR (clone BP774) recognizes the epitope of PRLR 1–14 from
humans and cross-reacts with PRLR from murine origins.
Cultured Cells
For the 3D models, ovarian, pancreatic, and prostate cancer cells were grown
on nonadhesive optical plates (MatTek) and then brought to the glass surface
that was precoated with 200 ml of growth-factor-reduced Matrigel (BD Biosci-
ences). Approximately 18,000–20,000 spheroid-like cells were plated in each
well of a 24-well plate and incubated at 37C for 1 hr to allow cells to seed
gradually. Spheroids were cultured with full medium containing 2% Matrigel
as previously described (Li and Lu, 2011).
Autophagic Flux Analysis
For FACS analysis of AVOs, cells were first stained with AO. Green (510–
530 nm) and red (>650 nm) fluorescence emissions from 1 3 104 cells illumi-
nated with blue (488 nm) excitation light were measured with a FACSCalibur
from Becton Dickinson. pGFP-RFP-LC3 plasmids were stably transfected
into epithelial ovarian cancer cells, and cells were visualizedwith amultiphoton
confocal microscope (TCS SP5 MP; Leica Microsystems) or analyzed by LSR
Fortessa Flow Cytometry (BD Biosciences).
Clinical Data
Tissue samples from 32 patients with histopathology-confirmed serous-type
primary epithelial ovarian cancer were obtained under a protocol (214/11)
approved by the Institutional Review Board at Poznan University of Medical
Sciences. The clinical and pathological characteristics recorded for the
patients enrolled in the study include menopausal status, tumor stage and
grade, details of surgical debulking, and any tumor recurrence. Median
follow-up duration for overall survival was 4.7 years. The plasma and tumor
tissues were analyzed for the proteins indicated.
Statistical Analysis
We performed Student’s t test (between two groups) or ANOVA (for all groups)
if normally distributed to compare continuous variables and theMann-Whitney
rank-sum test or Kruskal-Wallis test (for all groups) if nonparametric. Pairwise
differences in normally distributed variables in our treatment groups werecompared by the Tukey-Kramer statistic for multiple comparisons. A Bonfer-
roni adjustment (default value 0.05) was made based on the number of
pairwise comparisons within a treatment experiment using the formula:
a(a) = 0.05/k, where k is the number of comparisons against control. A p value
of <0.05 was considered significant. Error bars represent SEM.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, one table, and six movies and can be found with this article
online at http://dx.doi.org/10.1016/j.celrep.2014.03.009.
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